Backed by hundreds of peer-reviewed studies supporting its safety and efficacy, the CyberKnife System provides a pain-free, non-invasive option for patients who are looking for an alternative to surgery and for patients who have inoperable or surgically complex tumors. In addition, the CyberKnife System is increasingly being used as an alternative to conventional radiation therapy, allowing for a shorter course of treatment. CyberKnife treatment is typically completed in just one to five days, instead of the 40 or more treatment sessions typically required with conventional radiation therapy, and, unlike surgery, requires no recovery time.
About INDEC
Ad Statistics
Times Displayed: 31443
Times Visited: 833 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
Instituto Neurologico de Colombia (INDEC) is the largest and one of the only institutes in Latin America specialized in nervous system diseases. It is a non-profit organization that for more that forty years has been dedicated to provide high-quality and compassionate care to patients, in clinical neuroscience with neurological procedures of high and medium complexity. Highly qualified professionals and advanced technology allow us to provide excellent services. For more information, please visit www.institutoneurologico.org.
About Accuray
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company's leading edge technologies - the CyberKnife and TomoTherapy Systems - are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date, 635 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to worldwide radiation therapy market, emerging market penetration, reduced radiation exposure, accuracy, clinical efficiency, clinical applications, and clinical benefits. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading "Risk Factors" in the Company's report on Form 10-K for fiscal year 2011, and its reports on Form 10-Q for the first, second and third quarters of fiscal 2012. Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.
Back to HCB News
